Cancer is not limited to the physical dimension, but it also affects the entire biopsychosocial context in which the patient is inserted, making him more susceptible to psychiatric disorders such as depression and anxiety. These often require pharmacological intervention, and the use of psilocybin, a substance found in mushroom species, is one of the alterna...
A6-week study comparing the psychedelic psilocybin with the antidepressant escitalopram found no significant difference in antidepressant effects in patients with moderate to severe depression. Some secondary outcome measures favored psilocybin, but those analyses were not adjusted for multiple comparisons. Study results were published in the April 15, 2021 ...
Anorexia Nervosa (AN) is a major health problem with one of the highest mortalities and treatment costs of any psychiatric condition. Cognitive behavioural therapy (CBT) is currently the most widely used treatment for AN in adults but provides remission rates ≤ 50%. Treatment drop-out is exceedingly high and those that persevere with treatment often relapse,...
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression (TRD). Novel antidepressants with rapid and sustained effects...
After a cessation of almost 40 years, there is renewed interest into therapeutic applicationsof the serotonergic psychedelic psilocybin for the treatment of patients with various psychiatric disorders. PubMed was searched for clinical trials into "psilocybin" between 2000 and 2020, complemented by handsearching. Articles were also screened for explanatory mo...
Patients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen saw a rapid and lasting improvement in depression symptoms, a randomized open-label trial has found. These findings extend results of research that have suggested antidepressant effects for psilocybin in patients with canc...
Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the world is experiencing an episode of major depression in his or her lifetime, and it is estimated that major depression will rank second after cardiac disease as a cause of international medical morbidity by the year 2020. Depr...
Importance: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. Objective: T...
BACKGROUND: Psilocybin therapy has shown promise as a rapid-acting treatment for depression, anxiety, and demoralization in patients with serious medical illness (e.g., cancer) when paired with individual psychotherapy. This study assessed the safety and feasibility of psilocybin-assisted group therapy for demoralization in older long-term AIDS survivor (OLT...
BACKGROUND: Psilocybin has shown promise as a treatment for depression but its therapeutic mechanisms are not properly understood. In contrast to the presumed actions of antidepressants, we recently found increased amygdala responsiveness to fearful faces one day after open-label treatment with psilocybin (25 mg) in 19 patients with treatment-resistant depre...
Objective: The objective of this selective EBM review is to determine whether or not psilocybin is an effective treatment to reduce depression and anxiety in cancer patients with a diagnosis of an anxiety disorder, mood disorder, and/or stress disorder. Study design: Systematic review of three cross-over randomized placebo-controlled trials published in peer...
Psychiatry is in a crisis. Mental health disorders are on the rise worldwide and there are currently not enough efficient treatment methods that would meet the patients’ needs. Hence, the societal and economic costs of mental health problems are enormous, as well as the suffering of individuals afflicted by mental health problems. Lysergic acid diethylamide ...
The psychedelic psilocybin and the entactogen 3,4-methylenedioxymethamphetamine (MDMA) are being scientifically studied again after a long hiatus, and especially for their potential in the treatment of psychiatric disorders. Their profound effect on cognitive, perceptual, and affective processes have led to several clinical studies during the last decade tha...
Mental illnesses, especially depression, are a global problem that require new treatment options to those whose symptoms are resistant to the current ones. Psilocybin, which is a naturally occurring drug in mushrooms, has become a potential candidate. It affects the brain by deactivating certain areas, causing not only changes in perception and consciousness...
In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential ...
Psilocybin-Research.com
Searchable psilocybin and psilocin bibliometric database.